The Connected Clinician: Top Stories of the Week for October 27

Problems must be targeted before solutions can be met. The challenge of clinical investigation is in fully understanding what conditions are causing in patients before even developing a strategy in combating the condition. Much of MD Magazine's top stories this week pertained to uncovering problems. From understanding the context of increasing US heart failure rates, to expanding on the link between centralized retinal thickness (CRT) and vision loss, our content this week focused on health care's harder questions.

Air Pollution Deaths Reach New Global Highs

Sepsis Screening Possibly Linked to C. difficile Infection

Where to Target HIV Prevention and Care to Reach MSM

Revised Declaration of Geneva Could Replace Hippocratic Oath

The Prevalence of Adult Onset ADHD, Reconsidered

Many Patients Unaware of Risks of Double Dosing OTC Cold/Flu Medications

Hospital Infection Control Uses EHR to Track C. Difficile

Once Daily Single-Tablet HIV-1 Therapy Achieves Primary Endpoint

Alkermes Announces Schizophrenia Therapy Studies

Plazomicin Submitted for NDA in Treatment of Complicated UTI

In case you missed them, here's our Connected Clinician Top Stories of the Week:Ambient air pollution-related deaths now total more annually than AIDS, tuberculosis, and malaria combined.Broad spectrum antibiotics may be to blame for healthcare facility-onset CDI. HIV infection is hyperendemic among MSM throughout many areas of the US, specifically in the South.The most recent WMA revised declaration brings attention to possible physician burnout.Results showed that more than 80% of participants had their symptoms explained by other factors.It’s imperative healthcare providers strive to have a conversation with patients when prescribing medication.EHR tracks down a source of a common hospital-acquired infection tracing patient movements.Janssen’s darunavir-based STR, if approved, will be the only complete simplified regimen for HIV-1 in ART-naïve patients.ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.The drug has the potential to treat certain multi-drug resistant gram-negative pathogens like CRE.